Streetbeat News

Revenues

TRTX

Analysts have provided diverse opinions on TPG RE Finance Trust (NYSE:TRTX), with recent ratings ranging from bullish to bearish. The average 12-month price target is $7.38, reflecting a 13.54% increase from the previous target. Analysts from Raymond James, JP Morgan, B of A Securities, and Wells Fargo have updated their ratings and price targets, indicating varying expectations for TRTX's performance. The company, a commercial real estate finance entity, has shown a revenue growth of 6.95% but lags in net margin and ROE compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 1:01 pm

CLH

Clean Harbors (NYSE:CLH) was analyzed by 9 financial analysts, showing a shift towards more bullish ratings in the last quarter with an increase in the 12-month price target to $213.44 from $194.00. The company's financial performance indicates strong profitability and efficient management, with a notable revenue growth rate of 4.7% as of December 31, 2023, and a high net margin of 7.35%. Analysts' actions, including rating upgrades and price target adjustments, reflect optimism about the company's market position and financial health.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 1:01 pm

OGS

Recent analyst ratings for ONE Gas (NYSE:OGS) show a mix of bullish and bearish perspectives, with a total of 5 analysts offering their evaluations over the past three months. The average 12-month price target for OGS has been raised to $60.9, up 4.1% from the previous target of $58.50. Analyst actions include both upgrades and initiations, with price targets ranging from $58.00 to $64.50. Despite the mixed analyst outlook, ONE Gas faces financial challenges, including a significant revenue decline of -25.95% as of December 31, 2023, and below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 1:00 pm

TH

Target Hospitality (NASDAQ:TH) has been analyzed by 4 analysts, showing a mix of ratings from bullish to indifferent. The average 12-month price target is now $12.00, down from $13.00, reflecting a 7.69% decline. Analyst actions include lowering and maintaining ratings, with price targets adjusted accordingly. The company's financial performance shows a revenue decline of -17.2% over 3 months, but it outperforms in net margin, ROE, and ROA, indicating strong financial health despite revenue challenges.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 1:00 pm

AMD

AVGO

INTC

MRVL

NVDA

QCOM

Despite US-China tensions, China remains a crucial market for U.S. semiconductor firms like Nvidia, Intel, Broadcom, Qualcomm, and Marvell Technology. These companies continue to report greater revenues from China than the U.S., even amid stringent export controls targeting AI-related chips. U.S. firms have adapted by developing modified AI chips for China to comply with regulations, while maintaining a technological lead. The Semiconductor Industry Association has called for a de-escalation of tensions, as China moves towards semiconductor self-reliance and the U.S. plans further restrictions on Chinese chipmaking facilities.

Portfolio Pulse from Benzinga Neuro

April 12, 2024 | 12:58 pm

C

Citigroup reported a mixed financial performance for Q1, with a 7% decline in Markets Revenue, a 35% increase in Investment Banking Revenue, a 4% decrease in Wealth Revenue, and a 10% rise in US Personal Banking.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:08 pm

PRTG

Portage Biotech Inc. (NASDAQ:PRTG) is expanding its strategic alternatives review and pausing further enrollment in the ADPORT-601 clinical trial to extend its cash runway. The company is exploring options including partnerships, asset sales, a company sale, mergers, restructurings, or a wind down. There's no assurance that this process will result in any agreements or successful transactions.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:06 pm

OPTX

Syntec Optics has announced the launch of process development for a high-volume production line to manufacture disposable medical optics, marking a significant advancement in biomedical camera technology. This development, following nearly three years of concept proposals, positions Syntec Optics at the forefront of automated high-volume production in the US, leveraging their extensive expertise and advanced manufacturing capabilities. The addressable market for photonics-enabled biomedical segments was estimated at $201.1B in 2021, indicating a substantial market opportunity for Syntec Optics.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:05 pm

C

Citigroup projects its FY24 revenues to be between $80 billion and $81 billion, significantly surpassing the estimated $73.69 billion.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:05 pm

EKSO

Ekso Bionics has received the final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services for its Ekso Indego Personal product. The final payment level has been set at $91,031.93.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:04 pm